Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624179 | 1.00 | HPRT1 (0.56) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL9193126 | 1.00 | HPRT1 (0.56) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL15516660 | 0.90 | HPRT1 (0.55) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL29450587 | 0.90 | HPRT1 (0.55) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL172847 | 0.90 | HPRT1 (0.55) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL14669190 | 0.87 | CYP3A4 (0.53) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL14669198 | 0.87 | CYP3A4 (0.53) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL14669210 | 0.87 | CYP3A4 (0.53) | HPRT1CYP3A4CDK1CCNB1CCNE1 | |
| SCHEMBL2928584 | 0.85 | CYP3A4 (0.72) | HPRT1CYP3A4FGFR1SLC22A6 | |
| SCHEMBL384145 | 0.85 | CYP3A4 (0.72) | HPRT1CYP3A4FGFR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0533833-B1 | PHOSPHOROUS PRODUGS | GLAZIER ARNOLD (US) | 1995-12-20 | — | — | EP | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| EP-1753762-B1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-7582758-B2 | producing cyclic phosphonic acid diesters prodrugs, used to improve the oral bioavailability; by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid; Adefovir drug target delivery to liver | METABASIS THERAPEUTICS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1753762-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | Metabasis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123729-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| US-5733896-A | VIRICIDE FOR RETROVIRUS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-03-31 | — | — | US | disclosed |
| EP-0454427-B1 | Antiretroviral bases | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1995-12-06 | — | — | EP | disclosed |
| EP-0540707-B1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1995-11-15 | — | — | EP | disclosed |
| US-5352786-A | Di(2-propyl)esters of 1-fluoro-2-phosphonomethoxy-3-P-to-luenesulfonyloxypropanes, their producing and utilization | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-10-04 | — | — | US | disclosed |
| EP-0540707-A1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION. | CESKOSLOVENSKA AKADEMIE VED (CS) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992020692-A1 | DI(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | GILEAD SCIENCES, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020691-A1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | C^¿ESKOSLOVENSKÁ AKADEMIE VE^¿D (CS) | 1992-11-26 | — | — | WO | disclosed |
| EP-0454427-A1 | Antiretroviral bases | Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (CZ) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | PHOSPHO1, LPAR1, LPAR2 | HPRT1 778/4885CYP3A4 3253/4885CDK1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.